Iteos Therapeutics Inc ITOS.OQ ITOS.O is expected to show no change in quarterly revenue when it reports results on March 7 (estimated) for the period ending December 31 2024
LSEG's mean analyst estimate for Iteos Therapeutics Inc is for a loss of $1.06 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Iteos Therapeutics Inc is $21.39, above its last closing price of $6.85.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -1.15 | -0.89 | -1.05 | Missed | -18.1 |
Jun. 30 2024 | -1.04 | -1.04 | -0.18 | Beat | 82.7 |
Mar. 31 2024 | -0.97 | -1.26 | -1.07 | Beat | 14.8 |
Dec. 31 2023 | -0.93 | -1.03 | -0.85 | Beat | 17.7 |
Sep. 30 2023 | -1.14 | -1.20 | -0.90 | Beat | 25.2 |
Jun. 30 2023 | -0.98 | -1.03 | -0.96 | Beat | 6.8 |
Mar. 31 2023 | -1.00 | -0.99 | -0.44 | Beat | 55.8 |
Dec. 31 2022 | 0.33 |
This summary was machine generated March 5 at 13:32 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。